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Mitochondrial transcription factor A
p53R2
Cancere in cellular stress signaling, the tumor suppressor p53 modulates mitochondrial
respiration through its nuclear transcription factor activity and localizes to mitochondria, where it enhances
apoptosis and suppresses mitochondrial DNA (mtDNA) mutagenesis. Here we demonstrate a new conserved
role for p53 in mtDNA copy number maintenance and mitochondrial reactive oxygen species (ROS)
homeostasis. In mammals, mtDNA is present at thousands of copies per cell and is essential for normal
development and cell function. We show that p53 null mouse and p53 knockdown human primary
ﬁbroblasts exhibit mtDNA depletion and decreased mitochondrial mass under normal culture growth
conditions. This is accompanied by a reduction of the p53R2 subunit of ribonucleotide reductase mRNA and
protein and of mitochondrial transcription factor A (mtTFA) at the protein level only. Finally, p53-depleted
cells exhibit signiﬁcant disruption of cellular ROS homeostasis, characterized by reduced mitochondrial and
cellular superoxide levels and increased cellular hydrogen peroxide. Altogether, these results elucidate
additional mitochondria-related functions for p53 and implicate mtDNA depletion and ROS alterations as
potentially relevant to cellular transformation, cancer cell phenotypes, and the Warburg Effect.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The human mitochondrial genome is a 16.5-kb circular molecule
that is present at thousands of copies per cell in most tissues.
Mitochondrial DNA (mtDNA) is maternally inherited and, because it
encodes thirty-seven genes required for oxidative phosphorylation
(OXPHOS), is essential for normal development and sustained
function of cells and tissues throughout life [1]. Speciﬁcally, it encodes
thirteen core subunits of four of the ﬁve OXPHOS complexes, two
rRNA subunits of mitochondrial ribosomes, and twenty-two orga-
nelle-speciﬁc tRNAs. Mutations in mtDNA can affect the expression or
function of individual OXPHOS subunits, if they occur in one of the
protein-encoding genes, or can globally affect the OXPHOS system, if
they occur in a tRNA, rRNA, or a non-coding control region for
transcription or replication of the genome (e.g. the D-loop region). To
date, hundreds of pathogenic mtDNA mutations have been identiﬁed
that cause maternally inherited diseases, which, as a class, display, Yale University School of
Haven, CT 06520-8023, USA.
).
, CT, USA.
ll rights reserved.unexpected tissue-speciﬁcity and complex genetics [2]. Somatic
mutations in mtDNA also accumulate in tissues over time and have
been implicated in aging and age-related pathology [3]. Finally,
depletion of mtDNA is also pathogenic due to global disruption of
mitochondrial gene expression and can result from inherited muta-
tions in nuclear genes or represent a secondary consequence of other
disease conditions and treatments [4–7].
Recent estimates indicate that the mammalian mitochondrial
proteome comprises 1130–1500 proteins [8,9]. Since mtDNA encodes
only thirteen of these, the remaining majority are nuclear gene
products that are translated in the cytoplasm and imported into the
organelle. Consequently, mitochondrial dynamics is controlled by
gene expression programs in the nucleus [10] and signaling pathways
that relay information back and forth between these two organelles
[11]. These two processes are essential to maintain cellular home-
ostasis and alter mitochondrial biogenesis and function in response to
changing cellular needs or environmental conditions.
Mutations in nuclear genes that encode mitochondrial proteins
cause mitochondrial diseases that are inherited in a Mendelian
fashion. A subset of these involves factors that function directly in
mtDNA expression and maintenance (e.g. mtDNA polymerase, Pol γ,
and Twinkle helicase) [12]. In addition, nuclear mutations that affect
factors that do not reside in mitochondria, but nonetheless perturb
mitochondrial homeostasis or inter-organelle signaling pathways are
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mitochondrial genetic disruption is the identiﬁcation of mutations in
nuclear genes involved in deoxynucleotide metabolism as causative in
mtDNA-depletion syndromes (i.e., diseases characterized by severely
reducedmtDNA copy number in speciﬁc tissues) [13]. Recent efforts in
this area have identiﬁed mutations in the p53-regulated subunit
(p53R2) of ribonucleotide reductase (RNR) as causing a mtDNA-
depletion syndrome [14]. This provided bona ﬁde genetic proof in
humans and mice for the previously proposed role for the RNR in
mtDNA copy number regulation and stability in yeast and cultured
human cells [15–19]. In this same vein, we recently reported that
disruptions in RNR and associated mitochondrial perturbations may
also play a role in the disease Ataxia-telangiectasia [4], representing
one of the ﬁrst examples of a disease that may involve altered nuclear-
mitochondrial signaling.
The tumor suppressor p53 has documented roles in the response
to DNA damage and cellular stress. In addition, p53 also triggers pro-
oxidant genes and cell death pathways, presumably as a means to
remove extensively damaged or genetically unstable cells that can
contribute to cancer or other diseases. As a transcription factor, many
of its effects are mediated through expression of target nuclear genes
involved in the various processes it controls. However, effects of p53
that are independent of its transcription factor function have been
uncovered, as have novel functions beyond its stereotypical safe-
guarding role [20]. For example, p53 has been implicated in
regulating glucose metabolism and mitochondrial respiration
through expression of nuclear genes involved in glycolysis and
cytochrome oxidase assembly [21]. In addition, p53 physically
localizes to mitochondria where direct roles in apoptosis induction
[22,23], mtDNA stability and repair [24,25], and mitochondrial
transcription [26,27] have been postulated. This includes reported
physical interactions with Pol γ [24] and mitochondrial transcription
factor A (mtTFA or Tfam) [28], proteins with documented roles in
mtDNA replication/repair and mtDNA transcription/packaging,
respectively. Therefore, the impetus for the current study was to
examine the potential homeostatic role of p53 in maintaining
mtDNA copy number in primary human and mouse cell lines in
the absence of induced DNA damage.
2. Materials and methods
2.1. Cell culture and retroviral shRNA
C57/B6 wild-type and p53 null mouse neonatal ﬁbroblasts (MNFs)
(provided by Douglas Brash and Patrick Rochette at Yale) were
cultured in DMEM with 10% FCS. Primary human ﬁbroblasts
(GM07532) were purchased from Coriell Institute and grown in
EMEM with 15% FCS. The scrambled and p53 shRNA retroviral
constructs (provided by Kristin Yates and Daniel DiMaio at Yale)
were used as described [29]. Primary human ﬁbroblasts were infected
with each retrovirus for 24 h in the presence of 4 μg/ml polybrene,
followed by a 4-day selection in puromycin (0.6 μg/ml).
2.2. Mitochondrial DNA copy number assay
Total cellular DNA was extracted from 1×105 cells as described
[30] and resuspended in 20–50 μl of TE (pH 8.0). A quantitative, real-
time PCR method was used to determine the relative abundance of
mtDNA versus nuclear 18S rDNA using mitochondrial and nuclear
primer sets in two parallel PCR reactions as described previously [4].
Each 25 μl PCR reaction contained 14 μl of SYBR Green Mix (for ﬁnal
concentrations in reaction: 5% PCR grade DMSO [Sigma], 1:10,000
dilution of SYBR Green I [Molecular Probes], 0.3% Tween 20, 20 mM
Tris pH 8.3, 0.04% gelatin [Sigma], 50 mM KCl, 3 mM MgCl2, 200 mM
dNTPs,10 nM ﬂuorescein, 0.03 U Taq polymerase), 0.5 μl of each 25 μM
primer, and 10 μl of a 1:20–1:100 dilution of DNA in water. Thereactions were performed using a BioRad iCycler and analyzed using
iCycler version 3.1 software. Relative mtDNA copy number was
calculated as the ratio of the amount of ampliﬁcation obtained with
mtDNA versus nuclear 18S rDNA primer sets for each sample and
plotted normalized to the control group.
2.3. Western blotting
Western blotting was performed as described previously [4].
Brieﬂy, 50 μg of total cell protein were separated on 12% bis-
acrylamide gels and transferred to nitrocellulose membranes,
followed by overnight incubation with primary antibodies diluted
in 5% milk in TBST. Commercially available antibodies used were
obtained from the following sources: p53R2 (C-18), and p53 (FL-
393) antibodies, Santa Cruz; R1 (H-300), Chemicon; VDAC1/porin,
Abcam; and actin (20–33), Sigma. The rabbit polyclonal h-mtTFA
antibody was a gift from David Clayton. Following incubation with
HRP-conjugated secondary antibodies, Western Lightning ECL
reagent (Perkin Elmer) was used to detect signal on extra-sensitive
ﬁlm (GE Healthcare). Exposures were adjusted to ensure the signals
were in a linear range.
2.4. Mitochondrial membrane potential, mitochondrial mass and
ROS detection
For FACS analysis, 1×105 cells were stained in PBS with the
indicated ﬂuorescent dye for 25 min, washed, and resuspended in
200 μl PBS with 1% FCS. Individual cellular ﬂuorescence signals were
then analyzed using a FACSCalibur (BD Biosciences). Mitochondrial
membrane mass and mitochondrial potential were measured by
staining with MitoTracker Green FM (60 nM; Invitrogen) and
MitoTracker Red (80 nM; Invitrogen), respectively, for 25 min.
Dihydroﬂuorescein diacetate (10 μg/ml) was used to stain for total
cellular hydrogen peroxide, dihydroethidium (80 μM) for cellular
superoxide, and MitoSox Red (5 μM; Invitrogen) for mitochondrial
superoxide. Antimycin A treatment was performed by treating cells
with vehicle (ethanol) or 20 μMantimycin A (250 μMstock in ethanol)
for 20 min followed by staining with MitoSox Red. Unstained cells
were analyzed as controls and used to gate on live cells for ﬁnal
analysis using FlowJo software (TreeStar, Ashland, OR). Bar graphs
show combined median ﬂuorescence values of three independent
cultures, with at least 3000 cells analyzed for each. Histograms show
the ﬂuorescence-intensity distribution of cells as a percentage of total
gated cells (% max).
2.5. Determination of p53R2 and h-mtTFA mRNA transcript levels
Cells were seeded at 1×105 cell per T150 ﬂask and grown for 5 days
to mid-conﬂuence with one change of media. Cells were harvested and
homogenized using QIAshredder (Qiagen). RNA was extracted using
RNeasy PlusMini Kit (Qiagen) and elutedwith30 μl of RNase-freewater.
8 μg of total RNAwere converted into gene-speciﬁc cDNAusingM-MuLV
Reverse Transcriptase (New England BioLabs) according to the
manufacturer's protocol and 1 μM of reverse primer for actin, p53R2
and mtTFA (sequence below). cDNA was puriﬁed using QIAquick PCR
puriﬁcation Kit (Qiagen), eluted with 10 mM Tris (pH 8.5), dialyzed,
diluted 1:10 and 1:20 inwater and analyzed by real-time PCR using the
SYBR Green I protocol described above and primers listed below. Ct
values for p53R2 and h-mtTFAwere normalized to actin Ct values using
the equation 2ΔCt and are reported relative to themeanof the scrambled
group. Primers used for cDNA conversion and real-time PCR were:
actin, forward: 5′-TGGCACCACACCTTCTACAATGAGC-3′; actin, reverse:
5′-GCACAGCTTCTCCTTAATGTCACGC-3′; p53R2, forward: 5′-GTTCCA-
GAGGCTCGCTGTTTCTATG-3′; p53R2, reverse: 5′-TGATCTCCCTGACCCT-
TTCTTCTG-3′; h-mtTFA, forward: 5′-AGGGCGGAGTGGCAGGTATATAAA-
3′; h-mtTFA, reverse: 5′-CGACGTAGAAGATCCTTTCGTCCAAC-3′.
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The bars in the graphs represent at least three biological
replicates with error bars denoting the standard error of the mean.
In all graphs, values for both the experimental (i.e. p53 null or p53-
shRNA-expressing) and the control (i.e. wild-type or scrambled-
shRNA-expressing) groups were normalized to the mean of the
values obtained for the controls, so that the mean of the control
group in each experiment is always set to 1. All experiments were
repeated at least twice and representative experiments are shown.
p-values were calculated based on un-paired Student's t-tests, and
are denoted in the graphs as follows: pb0.05 (⁎), pb0.01 (⁎⁎), and
pb0.001 (⁎⁎⁎).
3. Results
3.1. p53 deﬁciency causes mtDNA depletion in primary mouse and
human ﬁbroblasts that is accompanied by reduced mitochondrial
membrane mass
Based on our previous study [4] showing that the ATM pathway
is essential for maintaining normal mtDNA copy number and
mitochondrial homeostasis, we hypothesized that p53, one of the
downstream targets of ATM kinase, may have a similar function. To
test the potential role of p53 in mtDNA replication and stability, we
ﬁrst examined mtDNA copy number in mouse neonatal ﬁbroblasts
(MNFs) derived from p53 null and wild-type mice. The p53 null cells
showed a 50% reduction in mtDNA copy number compared to
isogenic wild-type cells, consistent with p53 playing a role in
maintaining mtDNA (Fig. 1A). To address whether this effect on
mtDNA copy number has a bearing on mitochondrial function and
biogenesis in these cells, we measured mitochondrial membrane
potential and mass using MitoTracker dyes and FACS analysis.
Consistent with the mtDNA copy number results, p53 null cells
showed a 30% reduction in total mitochondrial membrane potential
and a 40% reduction in mitochondrial mass (Fig. 2A), again
implicating p53 in promoting normal mitochondrial function.
To test if this novel mitochondrial homeostasis function of p53 is
conserved in human cells, and also to conﬁrm that the mitochondrial
defects observed in murine cells were a direct consequence of p53
loss, we depleted p53 in primary human ﬁbroblasts using shRNA that
was introduced via retroviral transduction. The levels of p53 wereFig. 1. Depletion of mtDNA in p53 null mouse neonatal ﬁbroblasts and p53 knockdown
primary human ﬁbroblasts. (A) Relative mtDNA copy number (determined by
quantitative real-time PCR) inwild-type (+/+) and p53 null (−/−) MNFs. (B) Primary
human ﬁbroblasts expressing scrambled control (scr) or p53 shRNA (p53) were
analyzed for relativemtDNA copy number (graph) and p53 protein levels (Western blot).
Fig. 2. p53 null MNFs and human primary ﬁbroblasts treated with p53 shRNA show
mitochondrial membrane potential and mass defects. Mitochondrial membrane
potential and mass measured by FACS in (A) wild-type (+/+) and p53 null (−/−)
MNFs; and (B) primary human ﬁbroblasts expressing scrambled control (scr) or p53
shRNA (p53). (C) Western blot of porin as a mitochondrial marker with actin as a
loading control. Quantiﬁcation of porin signal normalized to actin is shown (graph) for
scrambled control (scr) or p53 shRNA (p53) expressing primary human ﬁbroblasts.reduced by at least half in the p53-shRNA expressing cells, which also
exhibited a 50% depletion of mtDNA compared to those transduced
identically with a scrambled shRNA negative control (Fig. 1B).
Mitochondrial membrane potential and mass were also decreased in
the human p53 knockdown cells by 20–30% (Fig. 2B), indicating that
the decrease in MitoTracker Red staining is most likely simply a
reﬂection of less mitochondrial mass, rather than a down-regulation
of membrane potential per se. The decrease in mitochondrial
biogenesis observed via MitoTracker staining was conﬁrmed by a
similar reduction in the mitochondrial protein marker porin inwhole-
cell lysates relative to actin (a cytoplasmic marker) (Fig. 2C). These
data largely conﬁrm our ﬁndings in primary mouse cells (Figs. 1A and
2A) and support a conserved role for p53 in maintaining mtDNA copy
number and mitochondrial abundance.
Fig. 3. p53 knockdown primary human ﬁbroblasts have reduced levels of p53R2 and h-mtTFA. Cells expressing scrambled control (scr) or p53 shRNA (p53) analyzed for (A) steady-
state levels of p53R2 and h-mtTFA by Western blot (actin is shown as a loading control); and (B) relative mRNA transcript levels of p53R2 and mtTFA normalized to actin message.
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the p53R2 subunit of ribonucleotide reductase
To begin to gain amechanistic perspective on themtDNA depletion
observed in p53 deﬁcient cells, we examined two factors previously
implicated in mtDNA copy number homeostasis, the mitochondrial
transcription and mtDNA-packaging factor, h-mtTFA/Tfam, and the
p53-regulated subunit of RNR, p53R2. The steady-state level of both of
these proteins was signiﬁcantly reduced in the p53-shRNA cell lines
compared to the negative control lines (Fig. 3A). The amounts of the
R1 and R2 subunits in the p53-depleted cells were unchanged and
modestly elevated, respectively (data not shown). The mRNA levels of
p53R2 were reduced by ∼35%, while h-mtTFA transcript levels were
unchanged in p53 knockdown cells (Fig. 3B), suggesting that p53R2 isFig. 4. Loss of p53 results in reduced mitochondrial superoxide and disrupted cellular ROS h
(O2−) and mitochondrial superoxide levels in primary human ﬁbroblasts depleted of p53 b
(scr). Histograms of representative experiments for scrambled (black line) and p53 shRNA (
B. FACS analysis of cellular superoxide in wild-type (+/+) and p53 null (−/−) MNFs. The
(gray shading) MNFs. C. FACS analysis of p53 knockdown human primary ﬁbroblasts tre
histogram shows a representative experiment with vehicle (black line) and antimycin A (likely down-regulated at the transcriptional level, while h-mtTFA is
down-regulated post-transcriptionally.
3.3. p53 has a pro-oxidant role in mitochondria and is required for
cellular ROS homeostasis
Certainly one of the predicted consequences of disrupted mito-
chondrial homeostasis is altered ROS production. In addition, p53 has
been implicated previously in both antioxidant and pro-oxidant
functions [20]. Therefore, we examined mitochondrial and cellular
ROS levels in p53-shRNA primary human ﬁbroblasts, using ﬂuorescent
ROS dyes MitoSox Red, dihydroﬂuorescein diacetate, and dihydroethi-
dium and FACS analysis. In the p53-depleted cells, we observed a
signiﬁcant increase in cellular hydrogen peroxide levels, and reducedomeostasis. A. FACS analysis of cellular hydrogen peroxide (H2O2), cellular superoxide
y shRNA (p53) compared to those treated with the negative scrambled control shRNA
gray shading) treated cells are shown underneath the corresponding bars in the graph.
histogram shows a representative experiment with wild-type (black line) and p53 null
ated with vehicle (ctrl) or antimycin A (AMA) and stained with MitoSox Red. The
gray shading) treated cells.
Fig. 5. Schematic representation of potential nuclear and mitochondrial functions of
p53 in mtDNA copy number maintenance and how loss of such functions could lead to
mtDNA depletion. At the top of the ﬁgure nuclear p53 is shown activating its known
target gene p53R2, which we propose occurs at some level even in the absence of DNA
damage. At the bottom of the ﬁgure, mitochondrial p53 is shown associated with
mtDNA (ragged circle) and its putative binding partners, mtTFA and Pol γ, that are each
required for mtDNA replication and maintenance. Loss of p53 is postulated to cause
mtDNA depletion by one or more mechanisms (see text for details), that involve (1) its
nuclear function as a transcription factor, or (2) its mitochondrial functions. Lack of p53
in the nucleus results in reduced expression of p53R2, dampened output of dNTPs by
the p53R2-R1 form of RNR (ovals at center right) and compromised mtDNA replication
or repair that causes mtDNA depletion. Reduced mtDNA levels could lead to reduced
levels of mtTFA protein if DNA binding is required for its stability. Lack of p53 in
mitochondria could alone cause mtDNA depletion if in fact p53 binds and stabilizes
mtTFA or is needed for optimal activity of Pol γ in mtDNA replication or repair.
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observed reduced mitochondrial superoxide in p53 null MNFs (Fig.
4B). MitoSox Red is a hydroethidine derivative that is oxidized by
superoxide to ethidium, which becomes highly ﬂuorescent when
intercalated into DNA. To rule out that reduced MitoSox Red
ﬂuorescence we observed in p53 deﬁcient cells was due to lower
mtDNA content in these cells, we treated p53 knockdown cells with
antimycin A for 20 min to induce mitochondrial ROS [31] without
increasing mtDNA copy number. Antimycin A treatment increased
MitoSox Red signal in p53 knockdown cells (Fig. 4C), conﬁrming that
mtDNA is not limiting for MitoSox Red staining in p53 deﬁcient cells.
These results indicate that in primary cells in culture p53 has a pro-
oxidant role in mitochondria with regard to superoxide, but both pro-
oxidant and antioxidant effects in the cell as a whole.
4. Discussion
There are three major outcomes of this study. First, primary mouse
and human cells that lack or have reduced levels of the tumor
suppressor p53, respectively, have depleted amounts of mtDNA that is
accompanied by a parallel reduction in mitochondrial mass (Figs. 1
and 2). However, in terms of magnitude, there was no consistent one-
to-one relationship between these parameters, suggesting that
mtDNA copy number and mitochondrial biogenesis are not necessa-
rily tightly linked. That is, the mtDNA depletion was always greater in
magnitude than the changes in mitochondrial mass, indicating a
larger role for p53 in mtDNA maintenance speciﬁcally. The observed
decrease in mitochondrial mass without a compensatory increase in
mitochondrial membrane potential (Fig. 2) indicates a reduced overall
mitochondrial oxidative capacity in p53 deﬁcient cells, consistent
with reported decreases in respiration [32]. Second, p53-dependent
mtDNA depletion was also accompanied by a reduction in mtTFA and
p53R2, two factors that have been linked previously to mtDNA copy
number maintenance [1]. And third, that there is a signiﬁcant
reduction of mitochondrial and total cellular superoxide levels when
p53 is down-regulated, but an increase in cellular hydrogen peroxide,
which points to complex regulation of cellular ROS homeostasis by
p53. The fact that all of these changes are occurring in primary, non-
transformed cells and in the absence of induced DNA-damage,
implicates mtDNA depletion and perturbed mitochondrial ROS
homeostasis as potential novel factors that promote p53-mediated
cancer cell phenotypes. These results and conclusions are discussed
further below.
The mechanism of mtDNA depletion accompanying the loss of p53
we report herein is worthy of discussion, as there are at least three
plausible explanations that are not mutually exclusive (Fig. 5). First,
the reduced expression of p53R2 is likely to be in part responsible for
the mtDNA depletion (Fig. 3). This protein is a direct transcriptional
target of p53 in the presence of DNA damage [33,34] and inactivating
mutations in its gene cause mtDNA depletion in humans and mice
[14]. We observe that p53R2 is down-regulated at both the mRNA
transcript and protein levels (Fig. 3), suggesting that p53R2 is a
transcriptional target of p53 even in the absence of DNA damage.
Reduced expression of p53R2 is expected to lead to diminished
amounts of R1-p53R2 complexes of RNR (Fig. 5), the form of the
enzyme that has been implicated speciﬁcally in providing dNTPs for
mtDNA replication and repair [18,19], and result in mtDNA depletion.
Consistent with this premise is the fact that disruptions in RNR have
also been implicated as a potential cause of mtDNA depletion in
cultured Ataxia-telangiectasia patient ﬁbroblasts [4]. A second
possibility is that it is the down-regulation of mtTFA in the absence
of p53 that we report here (Fig. 3A) that drives mtDNA depletion
(Fig. 5). The loss of mtTFA expression is reported to cause mtDNA
depletion [35,36], but its protein levels also passively mirror those of
mtDNAwhenmtDNA is depleted by treatmentwith ethidium bromide
or inhibitors of Pol γ [37,38]. Since we observed no change in thetranscript levels of mtTFA (Fig. 3B), we conclude that its reduction at
the protein level in p53 depleted cells is most likely due to its
degradation in response to reduced mtDNA levels (i.e. that it is
unstable when not bound to mtDNA) or some other form of post-
transcriptional regulation. This instability may be driven by loss of its
proposed physical interaction with p53 in mitochondria [28]. Given
that p53 is physically located in mitochondria [39–41], it is also
possible that loss of it in the organelle per se is the cause of the
observed mtDNA depletion (Fig. 5). This could be due to abrogation of
proposed interactions with mtTFA [28] and/or mtDNA Pol γ [24]
needed for efﬁcient mtDNA replication or repair. It is also possible that
p53 works as a transcription factor in mitochondria [26,27] and hence
its absence leads to reduced transcription-primed mtDNA replication
[42]. However, this latter possibility seems the least likely given recent
reports that p53 in mitochondria appears to act as a monomer, which
is not its typical transcription mode [43]. Deciphering which of these
pathways is primarily responsible for the mtDNA depletion in the
absence of p53 is an intriguing area ripe for future investigation.
Our results also point to a novel role for p53 in promoting
mitochondrial ROS. That is, loss of p53 results in decreased
mitochondrial superoxide levels (Fig. 3A). This effect could be
mediated through the rate of production of ROS by mitochondria or
by disruption of normal pro-oxidant or antioxidant pathways. The
antioxidant function of p53 is well-established and involves both its
ability to regulate the sestrins [44], anti-oxidant proteins responsible
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to the pentose phosphate pathway to generate NADPH needed for
enzymes involved in antioxidant defenses [45]. In addition, manga-
nese superoxide dismutase (MnSOD), the mitochondrial enzyme
responsible for the conversion of superoxide to hydrogen peroxide, is
also affected by p53 status, although reports on the nature of this
regulation are conﬂicting. One study shows that p53 positively
regulates MnSOD in Li-Fraumeni patient ﬁbroblasts and lymphoblasts
[46], while others show that p53 represses the MnSOD promoter in a
human carcinoma cell line [47] or reduces MnSOD levels when
introduced into HeLa cells [48]. Consistent with p53 having an
inhibitory effect on MnSOD, the physical binding of p53 to MnSOD in
mitochondria has also been reported to decrease MnSOD activity [49].
Our results are most consistent with an inhibitory role for p53 on
MnSOD, because, in this case, loss of p53 would result in increased
MnSOD activity that would account for the lowered mitochondrial
superoxide we observe in p53 deﬁcient cells (Fig. 4A, B). In addition,
increased MnSOD activity in the absence of p53 is predicted to
generate increased levels of hydrogen peroxide that would add to that
already culminating from the down-regulation of the sestrins. This
scenario would explain the higher levels of cellular hydrogen peroxide
we observe in p53-shRNA expressing primary human cells (Fig. 4A). In
summary, our results point to the importance of p53 in maintaining
ROS homeostasis, but show that its effects vary dramatically
depending on the speciﬁc ROS species and where they are gener-
ated/located. Of course, in addition to imbalances of antioxidant
systems described above, the decreased electron ﬂux through the
OXPHOS chain reported for p53 null cells [32] could certainly also
contribute to the observed decrease in mitochondrial ROS we observe.
In fact, it is probably a combination of both factors that is leading to
the particular cellular ROS proﬁles we describe herein (Fig. 4).
Given the key role loss of p53 plays in cancer, our results are
likely relevant in this regard. One key feature of many cancer cells is
increased dependence on glycolysis for ATP production even in the
presence of oxygen, when mitochondrial OXPHOS should more
signiﬁcantly contribute. This switch in metabolic behavior to
“aerobic glycolysis” was postulated by Warburg [50] to be driven
by mitochondrial dysfunction. While the precise mechanism of the
“Warburg Effect” remains unknown, recent studies of novel p53
targets may have provided some insight. For example, the loss of p53
has been reported to result in decreased OXPHOS Complex IV
activity and mitochondrial oxygen consumption, due to reduced
expression of a cytochrome c oxidase assembly factor Sco2, that is a
nuclear p53 target [32]. This was postulated by Hwang et al. to be a
major mechanism driving the Warburg Effect [21] that could work in
combination with up-regulation of glycolysis mediated by loss of
expression of other p53 targets (e.g. TIGAR [45]). This study expands
the list of speciﬁc mitochondrial defects that may be relevant to the
mitochondrial dysfunction involved in the Warburg Effect or in other
aspects of cancer progression to include mtDNA depletion and
altered mitochondrial and cellular ROS. For example, mtDNA
depletion could predispose mtDNA to instability and mutagenesis
[24] that could subsequently alter mitochondrial function in unique
ways that allow cellular transformation. Also, since ROS are
increasingly implicated in signal transduction processes [51] altera-
tions of mitochondrial ROS could impact signaling pathways that
promote cancer development. Determining the full range of
mitochondrial perturbations that contribute to cancer remains an
important goal.
5. Conclusion
In this study we have expanded our understanding of how p53
impacts mitochondrial homeostasis. In addition to direct effects on
respiration reported by others, we show here that p53 is required to
maintain normal mtDNA copy number and biogenesis and bothmitochondrial and cellular ROS homeostasis. These newly assigned
functions for p53 are likely involved in the important “gate-keeping”
function of p53 in cellular surveillance and relevant to how loss of its
functions promotes alterations in metabolism and tumorigenesis.
Acknowledgements
This work was supported by NIH grant NS056206 from the
National Institute of Neurological Disorders and Stroke awarded to
G.S.S, and M.A.L. was supported by NIH training grant T32GM007223
from the National Institute of General Medical Sciences. The authors
wish to thank Douglas Brash and Patrick Rochette for providing wild-
type and p53 null MNFs, Daniel DiMaio and Kristin Yates for reagents
and advice on retroviral shRNA, and David Clayton for the h-mtTFA
antibody.
References
[1] G.S. Shadel, Expression andmaintenance of mitochondrial DNA: new insights into
human disease pathology, Am. J. Pathol. 172 (2008) 1445–1456.
[2] D.C. Wallace, A mitochondrial paradigm of metabolic and degenerative diseases,
aging, and cancer: a dawn for evolutionary medicine, Annu. Rev. Genet. 39 (2005)
359–407.
[3] K.J. Krishnan, L.C. Greaves, A.K. Reeve, D. Turnbull, The ageing mitochondrial
genome, Nucleic Acids Res. 35 (2007) 7399–7405.
[4] J.S. Eaton, Z.P. Lin, A.C. Sartorelli, N.D. Bonawitz, G.S. Shadel, Ataxia-telangiectasia
mutated kinase regulates ribonucleotide reductase and mitochondrial home-
ostasis, J. Clin. Invest. 117 (2007) 2723–2734.
[5] W. Lewis, Cardiomyopathy, nucleoside reverse transcriptase inhibitors and
mitochondria are linked through AIDS and its therapy, Mitochondrion 4 (2004)
141–152.
[6] O. Elpeleg, H. Mandel, A. Saada, Depletion of the other genome-mitochondrial
DNA depletion syndromes in humans, J. Mol. Med. 80 (2002) 389–396.
[7] A.H.Hakonen, S.Goffart, S.Marjavaara, A.Paetau,H. Cooper,K.Mattila,M. Lampinen,A.
Sajantila, T. Lonnqvist, J.N. Spelbrink, A. Suomalainen, Infantile-onset spinocerebellar
ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal
complex I defect and mtDNA depletion, Hum. Mol. Genet. 17 (2008) 3822–3835.
[8] D.J. Pagliarini, S.E. Calvo, B. Chang, S.A. Sheth, S.B. Vafai, S.E. Ong, G.A. Walford,
C. Sugiana, A. Boneh, W.K. Chen, D.E. Hill, M. Vidal, J.G. Evans, D.R. Thorburn,
S.A. Carr, V.K. Mootha, A mitochondrial protein compendium elucidates
complex I disease biology, Cell 134 (2008) 112–123.
[9] M.F. Lopez, B.S. Kristal, E. Chernokalskaya, A. Lazarev, A.I. Shestopalov, A. Bogdanova,
M. Robinson, High-throughput proﬁling of the mitochondrial proteome using
afﬁnity fractionation and automation, Electrophoresis 21 (2000) 3427–3440.
[10] R.C. Scarpulla, Transcriptional paradigms in mammalian mitochondrial biogenesis
and function, Physiol. Rev. 88 (2008) 611–638.
[11] R.A. Butow, N.G. Avadhani, Mitochondrial signaling: the retrograde response, Mol.
Cell 14 (2004) 1–15.
[12] W.C. Copeland, Inherited mitochondrial diseases of DNA replication, Annu. Rev.
Med. 59 (2008) 131–146.
[13] A. Saada, Deoxyribonucleotides and disorders of mitochondrial DNA integrity,
DNA Cell Biol. 23 (2004) 797–806.
[14] A. Bourdon, L. Minai, V. Serre, J.P. Jais, E. Sarzi, S. Aubert, D. Chretien, P. de Lonlay,
V. Paquis-Flucklinger, H. Arakawa, Y. Nakamura, A. Munnich, A. Rotig, Mutation
of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes
severe mitochondrial DNA depletion, Nat. Genet. 39 (2007) 776–780.
[15] T.W. O'Rourke, N.A. Doudican, H. Zhang, J.S. Eaton, P.W. Doetsch, G.S. Shadel,
Differential involvement of the related DNA helicases Pif1p and Rrm3p in mtDNA
point mutagenesis and stability, Gene 354 (2005) 86–92.
[16] S.D. Taylor, H. Zhang, J.S. Eaton, M.S. Rodeheffer, M.A. Lebedeva, W. O'Rourke,
T.W. Siede, G.S. Shadel, The conserved Mec1/Rad53 nuclear checkpoint
pathway regulates mitochondrial DNA copy number in Saccharomyces
cerevisiae, Mol. Biol. Cell 16 (2005) 3010–3018.
[17] M.A. Lebedeva, G.S. Shadel, Cell cycle- and ribonucleotide reductase-driven
changes in mtDNA copy number inﬂuence mtDNA Inheritance without compro-
mising mitochondrial gene expression, Cell Cycle (Georgetown, Tex) 6 (2007)
2048–2057.
[18] P. Hakansson, A. Hofer, L. Thelander, Regulation of mammalian ribonucleotide
reduction and dNTP pools after DNA damage and in resting cells, J. Biol. Chem. 281
(2006) 7834–7841.
[19] G. Pontarin, P. Ferraro, P. Hakansson, L. Thelander, P. Reichard, V. Bianchi, p53R2-
dependent ribonucleotide reduction provides deoxyribonucleotides in quiescent
human ﬁbroblasts in the absence of induced DNA damage, J. Biol. Chem. 282
(2007) 16820–16828.
[20] K. Bensaad, K.H. Vousden, p53: new roles in metabolism, Trends Cell Biol. 17
(2007) 286–291.
[21] W. Ma, H.J. Sung, J.Y. Park, S. Matoba, P.M. Hwang, A pivotal role for p53: balancing
aerobic respiration and glycolysis, J. Bioenerg. Biomembr. 39 (2007) 243–246.
[22] J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, N.M. Droin, D.D. Newmeyer, M. Schuler,
D.R. Green, Direct activation of Bax by p53 mediates mitochondrial membrane
permeabilization and apoptosis, Science (New York, N.Y 303 (2004) 1010–1014.
334 M.A. Lebedeva et al. / Biochimica et Biophysica Acta 1787 (2009) 328–334[23] S. Erster, M. Mihara, R.H. Kim, O. Petrenko, U.M. Moll, In vivo mitochondrial p53
translocation triggers a rapid ﬁrst wave of cell death in response to DNA damage
that can precede p53 target gene activation, Mol. Cell. Biol. 24 (2004) 6728–6741.
[24] G. Achanta, R. Sasaki, L. Feng, J.S. Carew, W. Lu, H. Pelicano, M.J. Keating, P. Huang,
Novel role of p53 in maintaining mitochondrial genetic stability through
interaction with DNA Pol gamma, EMBO J. 24 (2005) 3482–3492.
[25] D. Chen, Z. Yu, Z. Zhu, C.D. Lopez, The p53 pathway promotes efﬁcient
mitochondrial DNA base excision repair in colorectal cancer cells, Cancer Res.
66 (2006) 3485–3494.
[26] K. Heyne, S. Mannebach, E. Wuertz, K.X. Knaup, M. Mahyar-Roemer, K. Roemer,
Identiﬁcation of a putative p53 binding sequence within the human mitochon-
drial genome, FEBS Lett. 578 (2004) 198–202.
[27] R.J. Donahue, M. Razmara, J.B. Hoek, T.B. Knudsen, Direct inﬂuence of the p53
tumor suppressor on mitochondrial biogenesis and function, FASEB J. 15 (2001)
635–644.
[28] Y. Yoshida, H. Izumi, T. Torigoe, H. Ishiguchi, H. Itoh, D. Kang, K. Kohno, P53
physically interacts with mitochondrial transcription factor A and differentially
regulates binding to damaged DNA, Cancer Res. 63 (2003) 3729–3734.
[29] K.E. Yates, G.A. Korbel, M. Shtutman, I.B. Roninson, D. DiMaio, Repression of the
SUMO-speciﬁc protease Senp1 induces p53-dependent premature senescence in
normal human ﬁbroblasts, Aging cell 7 (2008) 609–621.
[30] J. Sambrook, E.F. Fritsch, T. Maniatis, Molecular Cloning: A Laboratory Manual, 2nd
ed.Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989.
[31] J.F. Turrens, Mitochondrial formation of reactive oxygen species, J. Physiol. 552
(2003) 335–344.
[32] S. Matoba, J.G. Kang, W.D. Patino, A. Wragg, M. Boehm, O. Gavrilova, P.J. Hurley,
F. Bunz, P.M. Hwang, p53 regulates mitochondrial respiration, Science (New
York, N.Y 312 (2006) 1650–1653.
[33] H. Tanaka, H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei,
Y. Nakamura, A ribonucleotide reductase gene involved in a p53-dependent cell-
cycle checkpoint for DNA damage, Nature 404 (2000) 42–49.
[34] K. Nakano, E. Balint, M. Ashcroft, K.H. Vousden, A ribonucleotide reductase gene is
a transcriptional target of p53 and p73, Oncogene 19 (2000) 4283–4289.
[35] N.G. Larsson, J. Wang, H. Wilhelmsson, A. Oldfors, P. Rustin, M. Lewandoski,
G.S. Barsh, D.A. Clayton, Mitochondrial transcription factor A is necessary for
mtDNA maintenance and embryogenesis in mice, Nat. Genet. 18 (1998)
231–236.
[36] A. Goto, Y. Matsushima, T. Kadowaki, Y. Kitagawa, Drosophila mitochondrial
transcription factor A (d-TFAM) is dispensable for the transcription of mitochon-
drial DNA in Kc167 cells, Biochem. J. 354 (2001) 243–248.
[37] B.L. Seidel-Rogol, G.S. Shadel, Modulation of mitochondrial transcription in
response to mtDNA depletion and repletion in HeLa cells, Nucleic Acids Res. 30
(2002) 1929–1934.[38] J. Poulton, K. Morten, C. Freeman-Emmerson, C. Potter, C. Sewry, V. Dubowitz,
H. Kidd, J. Stephenson, W. Whitehouse, F.J. Hansen, et al., Deﬁciency of the
human mitochondrial transcription factor h-mtTFA in infantile mitochondrial
myopathy is associated with mtDNA depletion, Hum. Mol. Genet. 3 (1994)
1763–1769.
[39] B.A. Merrick, C. He, L.L. Witcher, R.M. Patterson, J.J. Reid, P.M. Pence-Pawlowski,
J.K. Selkirk, HSP binding and mitochondrial localization of p53 protein in
human HT1080 and mouse C3H10T1/2 cell lines, Biochim. Biophys. Acta 1297
(1996) 57–68.
[40] N.D. Marchenko, A. Zaika, U.M. Moll, Death signal-induced localization of p53
protein to mitochondria. A potential role in apoptotic signaling, J. Biol. Chem. 275
(2000) 16202–16212.
[41] N.D. Marchenko, S. Wolff, S. Erster, K. Becker, U.M. Moll, Monoubiquitylation
promotes mitochondrial p53 translocation, EMBO J. 26 (2007) 923–934.
[42] N.D. Bonawitz, D.A. Clayton, G.S. Shadel, Initiation and beyond: multiple functions
of the human mitochondrial transcription machinery, Mol. Cell 24 (2006)
813–825.
[43] K. Heyne, K. Schmitt, D. Mueller, V. Armbruester, P. Mestres, K. Roemer, Resistance
of mitochondrial p53 to dominant inhibition, Mol. Cancer 7 (2008) 54.
[44] A.A. Sablina, A.V. Budanov, G.V. Ilyinskaya, L.S. Agapova, J.E. Kravchenko, P.M.
Chumakov, The antioxidant function of the p53 tumor suppressor, Nat. Med. 11
(2005) 1306–1313.
[45] K. Bensaad, A. Tsuruta, M.A. Selak, M.N. Vidal, K. Nakano, R. Bartrons, E. Gottlieb,
K.H. Vousden, TIGAR, a p53-inducible regulator of glycolysis and apoptosis, Cell
126 (2006) 107–120.
[46] S.P. Hussain, P. Amstad, P. He, A. Robles, S. Lupold, I. Kaneko,M. Ichimiya, S. Sengupta,
L. Mechanic, S. Okamura, L.J. Hofseth, M. Moake, M. Nagashima, K.S. Forrester, C.C.
Harris, p53-induced up-regulation of MnSOD and GPx but not catalase increases
oxidative stress and apoptosis, Cancer Res. 64 (2004) 2350–2356.
[47] P. Drane, A. Bravard, V. Bouvard, E. May, Reciprocal down-regulation of p53 and
SOD2 gene expression-implication in p53 mediated apoptosis, Oncogene 20
(2001) 430–439.
[48] G. Pani, B. Bedogni, R. Anzevino, R. Colavitti, B. Palazzotti, S. Borrello, T. Galeotti,
Deregulated manganese superoxide dismutase expression and resistance to
oxidative injury in p53-deﬁcient cells, Cancer Res. 60 (2000) 4654–4660.
[49] Y. Zhao, L. Chaiswing, J.M. Velez, I. Batinic-Haberle, N.H. Colburn, T.D. Oberley,
D.K. St Clair, p53 translocation to mitochondria precedes its nuclear transloca-
tion and targets mitochondrial oxidative defense protein-manganese super-
oxide dismutase, Cancer Res. 65 (2005) 3745–3750.
[50] O. Warburg, On respiratory impairment in cancer cells, Science (New York, N.Y
124 (1956) 269–270.
[51] T. Finkel, Oxidant signals and oxidative stress, Curr. Opin. Cell Biol. 15 (2003)
247–254.
